IART

Let’s dig into the relative performance of Integra LifeSciences (NASDAQ:IART) and its peers as we unravel the now-completed Q2 surgical equipment & consumables - specialty earnings season. The surgical equipment and consumables industry provides tools, devices, and disposable products essential for surgeries and medical procedures. These companies therefore benefit from relatively consistent demand, driven by the ongoing need for medical interventions, recurring revenue from consumables, and long-term contracts with hospitals and healthcare providers. However, the high costs of R&D and regulatory compliance, coupled with intense competition and pricing pressures from cost-conscious customers, can constrain profitability. Over the next few years, tailwinds include aging populations, which tend to need surgical interventions at higher rates. The increasing integration of AI and robotics into surgical procedures could also create opportunities for differentiation and innovation. However, the industry faces headwinds including potential supply chain vulnerabilities, evolving regulatory requirements, and more widespread efforts to make healthcare less costly. The 4 surgical equipment & consumables - specialty stocks we track reported a satisfactory Q2. As a group, revenues beat analysts’ consensus estimates by 0.8% while next quarter’s revenue guidance was 1.6% below. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 13.9% since the latest earnings results. Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ:IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments. Integra LifeSciences reported revenues of $418.8 million, flat year on year. This print was in line with analysts’ expectations, and overall, it was a satisfactory quarter for the company with a beat of analysts’ EPS estimates but full-year revenue guidance meeting analysts’ expectations. "Our second-quarter performance reflects meaningful progress on our most important priorities. We are improving supply reliability, advancing quality, and returning products to market with discipline. The Braintree facility is now producing and ramping to support the planned SurgiMend relaunch later this year," said Stuart Essig, Chairman and CEO of Integra LifeSciences. Integra LifeSciences pulled off the highest guidance raise and highest full-year guidance raise, but had the slowest revenue growth of the whole group. Even though it had a relatively good quarter, the market seems discontent with the results. The stock is down 17.7% since reporting and currently trades at $16.26. Is now the time to buy Integra LifeSciences? Access our full analysis of the earnings results here, it’s free. With a portfolio spanning from vascular access catheters to minimally invasive surgical tools, Teleflex (NYSE:TFX) designs, manufactures, and supplies single-use medical devices used in critical care and surgical procedures across hospitals worldwide. Teleflex reported revenues of $570.3 million, up 28.9% year on year, outperforming analysts’ expectations by 2%. The business had an exceptional quarter with a beat of analysts’ EPS estimates and a solid beat of analysts’ full-year EPS guidance estimates. Teleflex delivered the fastest revenue growth in the group. However, the results were likely priced into the stock as it’s traded sideways since reporting. Shares currently sit at $135.77. Is now the time to buy Teleflex? Access our full analysis of the earnings results here, it’s free. Founded in 1983 and named after a pioneering vascular surgeon, LeMaitre Vascular (NASDAQGM:LMAT) develops and manufactures specialized medical devices used by vascular surgeons to treat peripheral vascular disease and other circulatory conditions. LeMaitre reported revenues of $70.38 million, up 9.6% year on year, falling short of analysts’ expectations by 1.7%. It was a disappointing quarter as it posted a significant miss of analysts’ EPS guidance for next quarter estimates and a significant miss of analysts’ EPS estimates. LeMaitre delivered the weakest performance against analyst estimates, weakest guidance update, and weakest full-year guidance update among its peers. As expected, the stock is down 24.9% since the results and currently trades at $79.41. Read our full analysis of LeMaitre’s results here. Pioneering minimally invasive surgery since its first da Vinci system was FDA-cleared in 2000, Intuitive Surgical (NASDAQ:ISRG) develops and manufactures robotic-assisted surgical systems that enable minimally invasive procedures across various medical specialties. Intuitive Surgical reported revenues of $2.89 billion, up 18.5% year on year. This result beat analysts’ expectations by 2.6%. It was a very strong quarter as it also produced a beat of analysts’ EPS estimates. Intuitive Surgical pulled off the biggest analyst estimate beat in the group. The stock is down 12.3% since reporting and currently trades at $352.87. Read our full, actionable report on Intuitive Surgical here, it’s free. Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership. Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products. By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals. Want to invest in winners with rock-solid fundamentals? Check out our Strong Momentum Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

A month has gone by since the last earnings report for Integra LifeSciences (IART). Shares have lost about 1.6% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Integra due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Integra LifeSciences Holdings Corporation reported second-quarter 2026 adjusted earnings per share of 56 cents, up 24.4% year over year. The figure beat the Zacks Consensus Estimate by 16.7%. GAAP earnings per share were 6 cents in the quarter compared with the year-ago period’s loss of $6.31 per share. Revenues of $418.76 million increased 0.8% and missed the consensus mark by 0.2%. IART’s Specialty Surgery Posts Growth Specialty Surgery revenues totaled $309.3 million, up 1.7% on a reported basis and 1.6% organically. Neurosurgery sales increased 1.9% organically, driven by Certas Plus, Bactiseal and CUSA as supply reliability and fulfillment improved. Instruments advanced 3.2% organically. ENT sales declined 1.9% organically as growth in MicroFrance ENT instruments was offset by weakness in other products. Management said reimbursement pressure on sinus balloons continued, while overall procedure demand remained generally consistent with its expectations. Integra’s Tissue Reconstruction Faces Pressure Tissue Reconstruction revenues were $109.5 million, down 1.9% on a reported basis and 2.0% organically. Wound Reconstruction declined in the mid-single digits, with growth in DuraSorb and the PriMatrix relaunch offset by lower MicroMatrix and Integra Skin sales. Integra Skin improved sequentially but faced a difficult year-ago comparison that included backorder clearance. Management said wound reconstruction was roughly flat for the first half of 2026 and remained within the range contemplated in the full-year outlook. IART’s Margin Performance In the reported quarter, adjusted gross profit totaled $256.9 million, up 1.8% year over year. The adjusted gross margin expanded 60 basis points (bps) to 61.3%. Selling, general and administrative expenses decreased 4.1% to $172.4 million, while research and development expenses fell 10.2% to $24.3 million.Adjusted EBITDA was $78.4 million, up 10.1% year over year. The adjusted EBITDA margin expanded 160 bps to 18.7%, reflecting manufacturing efficiencies, lower remediation spending and benefits from the company’s margin-improvement initiatives. IART’s Financial Position Integra exited the second quarter of 2026 with approximately $214.4 million in cash and cash equivalents compared with $236.8 million at the end of the first quarter. Cumulative net cash provided by operating activities at the end of the second quarter was $32.6 million, compared with the cash outflow of $2.3 million a year ago. Integra Provided 2026 & Q3 Guidance For full-year 2026, the company expects reported revenues to be in the range of $1.654-$1.695 billion, reflecting reported growth of 1.1% to 3.7%. The company reaffirmed its organic revenue growth guidance of 0.8% to 3.3%. Meanwhile, adjusted earnings per share are expected to be between $2.40 and $2.50. For the third quarter of 2026, Integra expects reported revenues in the range of $410-$425 million, representing reported growth of 2.0% to 5.7% and organic growth of 1.9% to 5.7%. Adjusted earnings are expected to be in the range of 53-61 cents per share. Since the earnings release, investors have witnessed a downward trend in estimates review. Currently, Integra has a average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. However, the stock was allocated a grade of B on the value side, putting it in the second quintile for value investors. Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of this revision indicates a downward shift. Notably, Integra has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Integra is part of the Zacks Medical - Instruments industry. Over the past month, Intuitive Surgical, Inc. (ISRG), a stock from the same industry, has gained 4%. The company reported its results for the quarter ended June 2026 more than a month ago. Intuitive Surgical reported revenues of $2.89 billion in the last reported quarter, representing a year-over-year change of +18.5%. EPS of $2.80 for the same period compares with $2.19 a year ago. Intuitive Surgical is expected to post earnings of $2.61 per share for the current quarter, representing a year-over-year change of +8.8%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged. Intuitive Surgical has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Integra LifeSciences Holdings Corporation (IART) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Image source: The Motley Fool. Wednesday, July 29, 2026 at 8:30 a.m. ET Senior Director of Investor Relations - Christopher Ward Chairman, President and Chief Executive Officer - Stuart Essig Chief Financial Officer - Lea Daniels Knight Operator: Good day, and thank you for standing by. Welcome to the Integra LifeSciences Second Quarter 2026 Financial Results. At this time, all participants are in a listen-only mode. Please be advised that today's conference is being recorded. After the speakers' presentation, there will be a question-and-answer session. To ask a question, please press *1 on your telephone and wait for your name to be announced. To withdraw your question, please press *1 again. I would now like to hand the conference over to your speaker today, Christopher Ward, Senior Director of Investor Relations. Christopher Ward: Good morning. And thank you for joining the Integra LifeSciences Second Quarter 2026 Earnings Conference Call. Joining me on the call are Stuart Essig, Chairman, President and Chief Executive Officer and Lea Daniels Knight, Chief Financial Officer. You should have the press release this morning announcing our second quarter 2026 financial results. We released an earnings presentation we referenced during the call is available at integralife.com under Investors, Events and Presentations, look for the file named second quarter 2026 earnings call presentation. Before we begin, I want to remind you that many statements made during the call may be considered forward-looking. Factors that could cause actual results to differ materially are discussed in the company's Exchange Act reports filed with the SEC. These factors are also detailed in the release. Also in our prepared remarks, we will reference reported and organic revenue growth. Organic revenue growth excludes the effects of foreign currency, acquisitions and divestitures. Unless otherwise stated, all disaggregated and franchise-level revenue growth rates are based on organic performance. Lastly, our comments today will include certain non-GAAP financial measures. Reconciliations of non-GAAP financial measures are included in today's press release, which is an exhibit to Integra's current report on Form 8-K filed today with the SEC. With that, I will now turn the call over to Stuart. Stuart Essig: Thank you, Christopher. And good morning to everyone on the line. We are encouraged by our second quarter results. We delivered on our commitments, achieved important milestones, and advanced our key priorities across the business. As a result, we are operating with greater consistency and strengthening our foundation for long-term growth. Revenue for the second quarter was $419 million up $27 million sequentially and in line with our May guidance. Adjusted earnings per share were above the high end of our guidance range, driven by our improved operating execution, and favorable tariff dynamics in the quarter. We are reaffirming our full year organic revenue growth outlook and adjusted EPS guidance. As our underlying operating expectations for the year remain unchanged. We are updating our reported revenue outlook to reflect the impact of foreign exchange. Lea will provide additional color on our guidance. Turning to our business segments, specialty surgery remains a core strength of the company. We hold a leading position in neurosurgery supported by a broad portfolio of differentiated products. long-standing customer relationships, and clinical interventions that are deeply embedded in the daily practice of neurosurgeons. Importantly, our leading positions in neurosurgery and instruments provide unique access to hospitals, IDNs, and GPOs, strengthening our enterprise commercial footprint and offering further growth opportunities across our broader portfolio. ENT remains an important emerging growth opportunity for Integra. We continue to invest in the pipeline, and are confident in our commercial team's ability to drive meaningful growth as the business and portfolio continue to develop. Turning to tissue reconstruction, we maintain a strong market position anchored by Integra Skin. Our flagship product and the market leader in dermal regeneration. The franchise is built on the broadest product portfolio available. Including Integra Skin, PriMatrix, AmnioExcel, MicroMatrix, and DuraSorb. This drives market leadership in complex wound reconstruction particularly in the hospital setting. Looking more broadly at the market, we believe Integra LifeSciences is uniquely positioned within the evolving reimbursement landscape. The combination of the breadth of our portfolio deep clinical evidence, a predominantly hospital-based business model, and pricing aligned with both hospital and outpatient reimbursement dynamics is difficult to replicate. As the market continues to adjust to the recent CMS reimbursement changes, we believe these strengths make us one of the best-positioned companies in wound reconstruction. We are also encouraged by the continued adoption of PriMatrix following its relaunch. Strong customer adoption reinforces our confidence in both the value of this product and our ability to successfully bring important products back to the market. Building on that momentum, we have successfully restarted manufacturing at our Braintree facility. Marking an important operational milestone for the company. We are now building inventory to support the commercial relaunch of SurgiMend 510(k) product in the fourth quarter. While the relaunch of SurgiMend represents an important near-term milestone, our broader objective is to expand the opportunity for both SurgiMend and DuraSorb through our dual PMA strategy in implant-based breast reconstruction. We are advancing toward an expanded label for SurgiMend, which we expect in 2027 with DuraSorb expected later that same year. Once approved, SurgiMend and DuraSorb would provide both biologic and synthetic solutions with the first two PMA indications for implant-based breast reconstruction expanding surgeon choice, and further strengthening one of Integra's key competitive advantages the breadth of our portfolio. Combined with our established presence in complex wound reconstruction, and our commercial capabilities, we believe this strategy positions us well for long-term growth in this market. Beyond our portfolio initiatives, we have begun to realize the benefits of the broader changes we have made in how the company operates. By better aligning our commercial organization, operating model, and transformation initiatives around the common set of priorities, we are improving execution and enhancing coordination across the business. Together, these efforts are creating a more efficient organization. And have contributed to cost savings in the second quarter. As we continue to improve supply reliability and operational performance, we see a clear path to further margin improvement in the coming years. That same focus on disciplined execution is reflected in our approach to capital allocation. Deleveraging continues to be our top priority. We exited the second quarter of 2026 at 4.1x total leverage down from 4.5x at year-end. And we remain on track to approach the upper end of our target leverage range by the end of 2026. Overall, we are advancing important milestones, improving how we operate, strengthening the foundation for sustainable growth. We remain focused on creating long-term value for customers, shareholders, and employees. With that, let me turn the call over to Lea for additional detail on our results and outlook. Lea Daniels Knight: Thank you, Stuart. Good morning, everyone. I want to begin by thanking our team for their continued strong execution in the second quarter. Turning to Slide 5, I will cover our second quarter financial results. Our second quarter revenues were $419 million representing 0.8% growth on a reported basis and 0.7% growth on an organic basis. These results build on the progress we have made over the past year and they reflect the steadier, more predictable performance we are now delivering quarter-to-quarter. Adjusted EPS for the quarter was $0.56 an increase of 24% compared to the prior year. Relative to our May guidance, revenue delivery and transformation savings were in line with our expectations and stronger overall operational execution. Drove performance to the high end of our guidance range. In addition, we benefited from $0.05 per share of tariff favorability versus our May guidance. Which contributed to our adjusted EPS performance above the high end of our guidance range. Gross margin for the quarter was 61.3% up approximately 60 basis points from 60.7% in the prior year reflecting efficiencies achieved across manufacturing operations and lower remediation spending. Adjusted EBITDA margin was 18.7%, up approximately 160 basis points versus 17.1% in Q2 2025, reflecting the benefits of the gross margin drivers I just discussed, together with contributions from our recent margin improvement initiatives. Cash flows from operations totaled $22.8 million in the second quarter and capital expenditures were $12.3 million Turning to slide 6, we will take a deeper dive into our Specialty Surgery revenue highlights for the second quarter. Specialty surgery revenue was $309.3 million representing 1.7% growth on a reported basis On an organic basis, revenue grew 1.6% compared to the prior year. Global Neurosurgery delivered 1.9% organic growth driven by Certas Plus, CUSA and BactiSeal as supply reliability and fulfillment have continued to improve. Sales of capital equipment were down approximately 1% as double-digit growth in CUSA was offset by a decline in smaller-ticket capital equipment during the period. We remain confident in the hospital capital environment and maintain a positive outlook for capital. For the year, Instruments grew low single digits benefiting from order timing relative to the first quarter. We continue to expect growth for the full year. In ENT, revenue declined low single digits reflecting continued growth in MicroFrance ENT instruments, offset by ongoing pressures in sinus balloons. Revenue in our international markets grew low single digits as improving supply is strengthening our ability to meet customer demand. Moving to our tissue reconstruction segment on Slide 7. Tissue Reconstruction revenues were $109.5 million down 1.9% on a reported basis and down 2% on an organic basis compared to the prior year. Within Wound Reconstruction, we continue to see positive growth contributions from DuraSorb and encouraging momentum following the relaunch of PriMatrix. While Integra Skin grew sequentially over the first quarter, it was down year-over-year as the second quarter of 2025 benefited from a significant backorder clearance for the product. MicroMatrix also declined in the quarter versus the prior year. For the first half of the year, wound reconstruction was approximately flat versus 2025 and its performance remains within the range of outcomes contemplated in our full year guidance. During the second quarter, private label sales grew 4.7%. Finally, international sales in tissue reconstruction grew low single digits driven by Integra Skin. If you turn to Slide 8, I will provide a brief update on our balance sheet capital structure and cash flow. Operating cash flow for the second quarter was $22.8 million compared to $8.9 million in the prior year. Our second quarter operating cash flow also reflects an $11 million final milestone payment related to the SeaSpine acquisition. For the first half of 2026, operating cash flow was $35 million compared to 2025, and we remain on track to deliver an approximate $150 million improvement in operating cash flow for the year driven by EBITDA growth, working capital efficiency, and an approximate $60 million reduction in cash expenditures related to EU MDR compliance and Braintree start-up costs. Free cash flow for the quarter was $10.5 million with a free cash flow conversion rate of 24%. As of June 30, net debt was $1.6 billion and our consolidated total leverage ratio was 4.1x within our current maximum allowable leverage of 5x. Reducing our leverage and continued debt repayment remain our top capital allocation priorities for 2026. We will continue to reduce our leverage over the course of the year and expect to approach the upper end of our target leverage range of 2.5x to 3.5x by the end of 2026. The company had total liquidity of approximately $496 million including approximately $274 million in cash and short-term investments with the remainder available under our revolving credit facility. Turning to slide 9, I will provide our consolidated revenue and adjusted earnings per share guidance for the third quarter and full year 2026. Before I begin, I would like to note that two weeks ago, there was flooding in the Cincinnati area that has resulted in operational disruption at our manufacturing site. We responded immediately implementing our business continuity plan, Based on our latest assessment of the inventory available at our distribution centers, our secondary supply sources and our insurance coverage, we do not expect the event to have a material impact on our revenue or EPS guidance for 2026. For the third quarter, we expect revenues to be in a range of $410 million to $425 million representing reported growth of 2% to 5.7% and organic growth of 1.9% to 5.7%. Turning to the full year 2026, we are reaffirming our organic revenue growth guidance range of 0.8% to 3.3% reflecting our expectation for a second half revenue increase driven by normal seasonality and continued improvement in supply. We are updating our reported revenue outlook to a range of $1.654 billion to $1.695 billion and reported growth of 1.1% to 3.7% to reflect the FX impact of a stronger U.S. dollar relative to our prior guidance assumption. Turning now to adjusted earnings per share guidance for the third quarter and full year. For the third quarter, we expect adjusted earnings per share in a range of $0.53 to $0.61. For the full year, we are maintaining our adjusted earnings per share guidance range of $2.40 to $2.50. The midpoint of our guidance range continues to reflect gross margin and adjusted EBITDA margin expansion, over 2025 of 60 and 100 basis points, respectively, as our underlying operating assumptions are unchanged. Lastly, we continue to evaluate how to optimize our capital structure. And we expect to refinance our outstanding bank debt in the second half of 2026 if market conditions permit. While we now anticipate somewhat higher interest expense in the second half of the year due to both the current rate environment and a potential refinancing, we expect those impacts to be offset by tariff favorability. We continue to expect to deliver earnings within our 2026 adjusted EPS guidance range and do not expect the higher interest expense to alter our broader earnings trajectory. Looking beyond 2026, we expect to offset potential interest expense headwinds through ongoing operational improvements and cost savings initiatives. For your reference, we have included the key assumptions underlying our third quarter and full year guidance as well as the key modeling inputs. On Slide 10. With that, I will turn the call back to Stuart. Stuart Essig: Thank you, Lea. Before we move to Q&A, let me close with a few thoughts. The second quarter was another step forward for Integra. We delivered on our commitments, advanced important milestones across the business, and continued to improve the way we operate. We are seeing the benefits of stronger execution and improved supply reliability. The organization is more aligned, and we continue to make meaningful progress on the opportunities that can drive future growth. Including the SurgiMend relaunch, our PMA strategy in implant-based breast reconstruction. As I spend time with our customers, I am increasingly excited about what lies ahead. We still have work to do, but I believe we are building real momentum and positioning Integra well for a strong future. What gives me confidence is the talent and dedication of our team at Integra, I want to thank our employees for their resilience, commitment to the business, and the way they continue to support our purpose every day. Their focus and perseverance are central to the progress we are making and to the future we are building. Thank you for your continued interest in Integra. Operator, please open the line for questions. Operator: Thank you. As a reminder, to ask a question, please press *1 on your telephone and wait for your name to be announced. To withdraw your question, please press *1 again. One moment for questions. Our first question comes from Vikramjeet Chopra with BMO Capital Markets. You may proceed. Anton: Good morning, Stuart. Hi, Lea. This is Anton on for Vic. Thanks for taking our questions. Maybe I will start with you. Second quarter EPS has beaten consensus by $0.08 but the guide was held intact. Can you talk a little bit more about what is driving a reaffirmed full year EPS outlook despite $0.03 organic outperformance? Is it just conservatism? Were there some spend anticipated in the second quarter that shifted to later this year? Or is there some kind of incremental expense headwind you are expecting in the second half? Lea Daniels Knight: Yes, certainly. Thanks, Anton, for the question. So yes, to your point, or our adjusted EPS was $0.56. We were $0.04 above our entire guidance range, $0.08 above the midpoint to your point. Notably, we were also 24% above our prior year EPS. Relative to our May guidance, what you saw is revenue delivery and transformation savings were in line with our expectations. We did see stronger performance from an operational execution perspective, which contributed to EPS being at the high end of the guide. In addition, though, we saw tariff favorability of about $0.05 per share. That is what drove us above the high end of our guide for the quarter. And to your point, in the second half, what we are now doing is that the upside that we saw from tariff favorability, which we had communicated in May, we have right-sized our tariff estimates or assumptions. We continue to believe our tariff exposure for the year will be about $0.10. And what we had as protection for any additional tariff changes, we are now using to mitigate an expectation of higher interest expense in the second half as a result of a planned refinancing transaction. So to your point, we do not expect, any operational headwinds to offset some of the upside that we saw, but we do expect to see interest expense headwinds. Anton: Alright. Great. I appreciate that color. And, Stuart, you have you have appointed a new chief commercial officer and are going on commercial offense. Just looking at the business, you know, where is the organization under-indexed today? Call points, GPO penetration, geographic coverage? And what are the areas that you are kind of targeting to reinvigorate the commercial engine over the next 12 to 18 months? Thanks. Stuart Essig: Let me start with very positive news, which is our supply situation is improving and has improved dramatically, and that is allowing our organization to be more proactive, to go on the offense. The new divisional and commercial structures have been implemented, including our new chief commercial officer and also, new division leaders reporting into that role. So the focus is on accountability. Faster decision-making, stronger ownership, broader enterprise contracting. And deeper customer and hospital engagement. I want to reiterate enterprise. We have a really good set of relationships with GPOs and IDNs. Which have really been built around our, neuro business and specialty surgery. But that leaves a lot of opportunity to expand those relationships into tissue reconstruction and ENT, and it is just a natural thing to add those products to our national account. Contracts. So our focus is on better deployment, coordination, using the current organization more effectively. The only real increase we expect in sales force is going to be, towards SurgiMend as it ramps, and that will be consistent with the original plan for SurgiMend, as it begins to grow. So what we do not see is a broader strategy reset. There is not a sales force restructuring. It is really just a way of reinforcing our positioning with customers. Operator: Thank you. Our next question comes from Ryan Zimmerman with BTIG. Izzy: Good morning, Stuart, Lea. This is Izzy on for Ryan. Thanks for taking the question. Stuart, I was trying to start with you. It has been a couple of months since you have stepped back into the CEO role here at Integra, and I was curious what you have seen in that time that has been kind of in line with your expectations and if there has been anything that maybe you did not expect. Stuart Essig: So first of all, I am very happy with what I found. I would say all of our focus as a leadership team is on improving execution, I want to underscore, I do not think the company needs a strategic reset. We have got strong market positions. We participate in really attractive end markets. Specialty surgery end markets like neuro and ENT and plastic and reconstructive surgery. And our products are clinically important. They are used in critical situations for patients' life and well-being. Our leadership team and the continuity in our leadership team is supporting execution, accountability, and consistent progress. So I really have not seen a need for reset. What I do see is an opportunity to continue to invest in our organization and drive simplification and accountability. Izzy: Got it. Thank you. And I think to the question prior to me, Stuart, you mentioned that SurgiMend is expected to come back prior or in line with prior expectations. I was hoping you could maybe quantify that a little bit more ahead of that fourth quarter launch and maybe some of the expectations into 2027? Thanks for taking the questions. Stuart Essig: Sure. So first, let me talk a little bit about how we have been doing in the market pre-SurgiMend. We sell DuraSorb into the market with, again, a separate smaller sales force. We have been driving DuraSorb share and growth consistently in the double digits. So, we continue with that sales organization to be asked, when are we going to get SurgiMend relaunched? And, how quickly we can bring it to market? So we have real confidence in the demand for that product from legacy customers as well as new customers. The market mix in terms of demand for tissue, has been moving from human tissue to xenograft and to resorbable synthetics. That really plays to our SurgiMend portfolio and our DuraSorb and our DuraSorb portfolio. So we expect share recapture to build over multiple quarters with SurgiMend. And I would remind you that our 2026 guidance does not assume any meaningful SurgiMend contribution. We do expect to launch it in the fourth quarter. And then we expect a modest recovery I think I would say something to the effect of 50% of its historical performance of $40 million and in line with our PriMatrix launch, which has been going very well and where we seem to be driving relatively quickly about 50% of the legacy revenues. Operator: Thank you. Our next question comes from Ravi Misra with Truist Securities. You may proceed. Ravi Misra: Hi, good morning. Thank you for taking the question. So just on the revenue guide, can you maybe talk about what gets you to the high end or the low end of the Q3 guide? And while we are at it, 2027 kind of consensus has growth acceleration. On the top line. Just curious, with all these products coming to market, potential indication expansion for your tissue surgery. And how are you-- are you comfortable with where the street sits? Thanks. And I have one follow-up. Lea Daniels Knight: Certainly. Thanks for the question, Ravi. So to your first part of your question regarding our 2026 guide, high and low, So reaffirming our full year organic revenue growth guidance of 0.8% to 3.3% We did update our reported revenue range just to reflect FX. We get to the high end of that guide, through stronger supply reliability, stronger seasonal demand, as well as faster realization of our cost savings The low end reflects a more measured pace of supply recovery as well as second half execution. So that is the high and the low. To your question on 2027, as you know, we do not provide 2027 guidance during this call. We will do that officially in February. But I can give you a way to think about a performance in 2027. So on the top line, through revenue, we do expect to see growth in 2027 versus 2026. But like the approach we took in 2026, we are going to continue to be very prudent with respect to our assumptions on the pace of supply as well as share recovery. Throughout the year. From an EPS perspective, we do expect to be able to offset the incremental interest expense headwind that I talked about earlier as a result of a second half 2026 refinancing, through additional cost savings. When we talked about our 2026 initiatives earlier, we indicated that not only were they going to deliver the $25 million to $30 million in cost savings that we projected for 2026, but on an annualized basis, they would deliver an incremental $10 million to $15 million in 2027. Additionally, we expect to see remediation and transformation costs come down as we continue to strengthen our quality as well as stabilize our supply. And all of these things together should allow us to see EPS growth faster than the rate of sales growth. And then finally, on cash flow, we expect to see continued improvement in terms of cash flow generation as we work to improve our overall quality of earnings. Ravi Misra: Great. Thank you very much. Super helpful color. And then just one last follow-up for me. Just in ENT, I think your performance was a little bit better than we expected. Still a year-over-year decline, I think. But can you talk about outlook here? I mean, seems instruments are doing well. Curious around the reimbursement headwinds in MicroFrance, and then maybe how elective procedures are shaping up in this space. Thanks a lot. Lea Daniels Knight: Yeah, certainly. So from an ENT perspective to your point, Q2 did decline low single digits. We did continue to see growth on the MicroFrance instruments part of the business, but that was more than offset by the continued reimbursement pressures that you mentioned on the sinus balloons part. Of the business. We did indicate as part of our Q1 results that we did expect ENT to be down on a full year basis. And that continues to hold true and is reflected in our guide at this point in time. Our focus going forward will be to focus on innovation in order to drive growth in ENT in the long-term and where we see those kind of more innovative segments are in navigated systems as well as Eustachian tubes. To your point on procedures, you know, and I will talk broadly because, you know, as we look across the business, overall procedural demand has remained generally consistent with our expectations The majority of our business, if you remember, is in trauma, and acute care versus, truly elective procedures. And so while there may be varying impacts across procedures as well as end markets, right now we cannot see any specific evidence that we are seeing any unusual impacts from, whether it be ACA subsidies or any other sort of insurance enrollment trends. And so believe the procedures and care settings that we operate in provide some protection for us and have not seen any real impacts. Thank you. Operator: Our next question comes from Lawrence Biegelsen with Wells Fargo. You may proceed. Ross Osborn: Hi. Good morning. This is Ross Osborn for Larry. So starting off, I realized Integra Skin had a tough comp. But ignoring the prior year, how would you rate the level of demand you are seeing today? And how should we think about contribution to next year? Lea Daniels Knight: Yes. So for Q2, we did see a decline in wound reconstruction. There were two parts to that. It was driven by Integra Skin as well as MicroMatrix. To your question specifically on Integra Skin, revenue was actually up sequentially as you look Q2 versus Q1. And so the performance versus a year ago was really due to kind of that tough year ago comp. Driven by backorder clearance that we saw in Q2 2025. And so from an Integra Skin perspective, we expect to build on the momentum that we have seen in terms of sequential revenue lift. Through the balance of the year. And then as it relates to MicroMatrix, the decline there reflects competition based on new entrants in the powder form. In total, wound reconstruction through the first half was about flat, and that is consistent with what is currently contemplated in our guidance. Ross Osborn: Okay. Great. And then what is the latest on MediHoney? And how should we think about that as a growth contributor in 2027? Stuart Essig: Yes. Why do not I grab MediHoney? First of all, we continue to advance the work to bring MediHoney back to market in 2027. We are including nothing in our 2026 guidance for MediHoney. And, we will continue to move forward with an expectation of bringing, the product back to market in 2027. It is in significant demand, and so we are confident in our ability to regain share over time as we bring the product back. Ross Osborn: Thanks for taking our questions. Operator: Thank you. Our next question comes from Travis Steed with Bank of America. You may proceed. Raymond: This is Raymond on for Travis. Thanks for taking our question. Just to build on the previous question on wound reconstruction, how should we be thinking about performance in the second half now with the return of PriMatrix and DuraSorb strength building. And then with SurgiMend, I appreciate that the contribution in 2026 is not as material, but maybe more into 2027. When can we expect the wound reconstruction business as a whole to return to more sustainable strength? Stuart Essig: So let me take a crack. First, our relaunch of PriMatrix is going, I would say exceptionally well. Our numbers are in line with our expectation. And we are seeing significant early signs of customer reengagement. Approximately nine months into the relaunch, the revenues recovered to slightly more than 50% of the pre-recall levels. And, PriMatrix continues to increase sequentially, quarter-over-quarter. I would say, one of the upsides of our recovery is that not only are we winning back prior customers, but our commercial team has been identifying additional opportunities based on many of the learnings that we had, while the products were off the market. Let me take a second on SurgiMend. Braintree is actively manufacturing SurgiMend, and we consider that a key operational milestone for Integra. Our near-term focus is building inventory to support a phased and disciplined Q4 relaunch. With sufficient inventory expected for the launch. We will have a controlled market relaunch applying what we have learned from PriMatrix to the way we relaunched the product, and we will start by engaging the historical highest-volume users and the KOLs first. Braintree was built with a quality system designed to meet the highest regulatory standards. And, again, we are not assuming any meaningful SurgiMend contribution in 2026. Raymond: Got it. Okay. Thank you. I guess on SurgiMend, maybe just to build and looking into 2027, I appreciate that. The FDA has cleared the PMA contingent on a successful inspection, is there a window in which we can expect the FDA inspection to occur? Have you maybe submitted a request for them to come visit? How should we be thinking about the timeline for breast reconstruction? Stuart Essig: Yes. Let me open the question a little bit more broadly to SurgiMend and DuraSorb, both of which are working their way toward a PMA label. So first, let me talk about SurgiMend. So as you acknowledge the clinical safety and efficacy review is complete, and we have an approvable decision from FDA already in place. So the PMA is now pending a successful pre-approval inspection at Braintree, which, we will be ready for, this year. For DuraSorb, enrollment and follow-up are complete. And data analysis is underway. So, that is moving on a slower timeframe than SurgiMend. And like SurgiMend, the PMA will also require a manufacturing facility pre-approval inspection. Obviously, always timing for any approval is up to the FDA. But we are expecting approval for SurgiMend earlier in 2027. and later in the year for DuraSorb. I will remind you all of our warning letter action items are expected to be implemented by the end of 2026. But ultimately any inspection and approval timing remain subject to the FDA. Raymond: Got it. Raymond: Thank you very much. Operator: Thank you. Our next question comes from Robbie Marcus with JPMorgan. You may proceed. Alan: Hi, thanks for the questions. This is Alan on for Ravi. I joined a little bit late, so sorry if this has been asked already. But when I look at your performance down the P&L this quarter, I definitely saw much better SG&A control. I think we have been seeing that on a good trajectory recently, when we think about the trajectory for the balance of the year, how should we think about you know, balancing continued SG&A controls with your efforts to get some of these new products back online. Lea Daniels Knight: Yeah. So let me take that Alan. Thank you for the question. So in terms of, cadence of the year of how we deliver against our guide, what you will see is, you know, we talked about from a revenue lens, you know, Q1, we saw a step up from Q1 to Q2 of about $27 million that is exactly what we laid out as part of our May guidance. Our Q3 guide keeps Q2 and Q3 about flat. And then we will see another step up in Q4 of about $25 million. So that is the cadence we described in May. It is how we have been executing through Q2 and how we continue to expect to execute through the balance of the year. On the cost side of the equation, if you recall, when we instituted or implemented the initiatives that were going to drive $25 million to $30 million of savings this year. What we said is the actions and activities have been implemented as of Q1, but we would realize acceleration of those savings as we move throughout the year. So that is going to be the driver to be able to drive additional leverage from an SG&A perspective for each quarter as we move forward from Q3 on for the balance of the year. And because it is tied to those initiatives, right, the very strategic part of our transformation in terms of operating model, how we are building new ways of working, we can do that while also making sure that we execute flawlessly against the planned launches for SurgiMend, as well as against the remainder of our remediation commitment. Alan: Got it. Thanks. And I heard your answer on, you know, the impact of ACA subsidies, how you are kind of insulated from that. But just curious on the, you know, the CapEx side of the equation. And again, sorry, if you have already answered the question, but just generally, the health of the broader CapEx market. Lea Daniels Knight: So our capital market? Yes. So our capital business saw strong growth in CUSA for the quarter. That performance was offset by some of our smaller-ticket capital equipment, but overall, we still believe our funnel remains healthy and the broader market remains healthy for capital. Alan: Thank you. Operator: Our next question comes from Jayson Bedford with Raymond James and Associates. You may proceed. Elena: Hi. This is Elena for Jason. Thanks for taking my question. I have one on guidance. You expect Q3 organic growth to be an acceleration from the first half levels. What gives you confidence in this guide, especially given the tough prior year comp? And can you talk about the moving pieces that contribute to growth? Lea Daniels Knight: Yes. So, yes, let me level set because a year ago in Q3, we actually had experienced two supply, interruptions. That actually drove performance down for that quarter. So as we now lap that period, we have an easier comp if you will, Q3 2026 versus 2025. So that describes part of the performance that we expect to deliver and what is currently reflected in the guide. But in addition to that, as we move through the year, what was also communicated is we continue to have supply improvements. We continue to see momentum across parts of our business particularly in neurosurgery, and expect to see more momentum in Integra Skin, and as we already discussed, with the return of SurgiMend in Q4. And while that in and of itself for the quarter will not be a material contribution, it still marks a very significant milestone in terms of getting that product back into the market. Elena: Okay. Thank you. And I also had a question on the leadership changes. Could you please share more on why now is the right time for this change, and what are the priorities for these businesses going forward? Stuart Essig: Sure. So leadership change is really reflected only in the commercial organization, and it really reflects a succession process. Our neuro leader, our specialty surgery leader, was promoted to chief commercial officer. And in each of the divisions, we promoted new division presidents. But in each case, they came from inside our business and come with significant knowledge and following within our organization. We bring together the leadership of the two divisions which then, allows us to coordinate our enterprise activity where we see a lot of opportunity to leverage our GPO and IDN presence that is really on the, surgical side and drive it into the tissue reconstruction and ENT side. So I would not think of this as a, significant change in leadership as opposed to an evolution of leadership where we are getting even more opportunity to leverage our internal leaders throughout the commercial part of the business. Operator: Okay. Thank you. This concludes the conference. Thank you for your participation. You may now disconnect. Before you buy stock in Integra LifeSciences, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Integra LifeSciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $397,405!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,344,091!* Now, it’s worth noting Stock Advisor’s total average return is 953% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of August 7, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Integra (IART) Q2 2026 Earnings Call Transcript was originally published by The Motley Fool

Integra LifeSciences’ second quarter results reflected ongoing business challenges, as management attributed the quarter’s flat revenue to ongoing reimbursement pressures in certain product lines and challenging year-over-year comparisons, especially in the tissue reconstruction segment. CFO Lea Daniels Knight acknowledged that, “the quarter’s outperformance in adjusted EPS was largely driven by operational execution and favorable tariff dynamics,” but reiterated that the company is operating in a complex environment marked by reimbursement and competitive challenges. Is now the time to buy IART? Find out in our full research report (it’s free). Revenue: $418.8 million vs analyst estimates of $417.7 million (flat year on year, in line) Adjusted EPS: $0.56 vs analyst estimates of $0.48 (15.8% beat) Adjusted EBITDA: $78.41 million vs analyst estimates of $73.52 million (18.7% margin, 6.7% beat) The company reconfirmed its revenue guidance for the full year of $1.67 billion at the midpoint Management reiterated its full-year Adjusted EPS guidance of $2.45 at the midpoint Operating Margin: 9.6%, up from 7.9% in the same quarter last year Organic Revenue was flat year on year (beat) Market Capitalization: $1.39 billion While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Anton Hsieh (BMO Capital Markets) asked why full-year EPS guidance was not raised despite the Q2 beat; CFO Lea Daniels Knight explained that tariff gains offset higher expected interest expense from refinancing, so operational headwinds are not anticipated. Izzy Karp (BTIG) questioned CEO Stuart Essig about his recent return to the CEO role; Essig emphasized no need for a strategic reset, instead focusing on improved execution and accountability within the leadership team. Ravi Misra (Truist Securities) asked about what would drive results to the high or low end of guidance; Daniels Knight pointed to supply reliability and seasonal demand as key swing factors, with cost savings and execution determining the outcome. Ross Osborn (Wells Fargo) inquired about current and future demand for Integra Skin; Daniels Knight cited sequential revenue growth and expects to build on this momentum, but flagged ongoing competition and prior year comparison challenges. Raymond Zhang (Bank of America) asked about the timing and impact of SurgiMend’s relaunch; Essig confirmed a disciplined Q4 launch with a controlled rollout, leveraging lessons from PriMatrix and emphasizing a gradual ramp toward historical performance. In upcoming quarters, the StockStory team will closely monitor (1) the phased commercial relaunch of SurgiMend and early demand signals from both legacy and new customers, (2) the pace and sustainability of cost savings from the current transformation initiatives and their effect on margins, and (3) signs of supply chain stability and recovery in key product lines, especially in tissue reconstruction and neurosurgery. The completion of regulatory milestones for SurgiMend and DuraSorb will also be critical markers for future growth potential. Integra LifeSciences currently trades at $17.88, down from $19.76 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free for active Edge members). ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time. Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE. Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.

For the quarter ended June 2026, Integra LifeSciences (IART) reported revenue of $418.76 million, up 0.8% over the same period last year. EPS came in at $0.56, compared to $0.45 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $419.6 million, representing a surprise of -0.2%. The company delivered an EPS surprise of +16.67%, with the consensus EPS estimate being $0.48. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Integra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Organic Revenue Growth: 0.7% compared to the 0% average estimate based on two analysts. Revenue- Tissue Technologies- Wound Reconstruction and Care: $81.31 million versus the two-analyst average estimate of $85.7 million. The reported number represents a year-over-year change of -4.1%. Revenue- Tissue Technologies- Total: $109.49 million versus $113.2 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -1.9% change. Revenue- Codman Specialty Surgical- Total: $309.27 million versus $303.91 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +1.8% change. Revenue- Tissue Technologies- Private Label: $28.19 million compared to the $27.5 million average estimate based on two analysts. The reported number represents a change of +4.8% year over year. View all Key Company Metrics for Integra here>>> Shares of Integra have returned +10% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Integra LifeSciences Holdings Corporation (IART) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management attributed the second quarter performance to improved operating execution and favorable tariff dynamics, leading to earnings above the high end of guidance. The Specialty Surgery segment remains a core strength, leveraging leading positions in neurosurgery to provide unique hospital access and strengthen the broader enterprise commercial footprint. In Tissue Reconstruction, the company is navigating the evolving CMS reimbursement landscape by utilizing its hospital-based model and broad portfolio to maintain market leadership. The successful restart of manufacturing at the Braintree facility marks a critical operational milestone, enabling inventory building for the upcoming SurgiMend relaunch. A new commercial leadership structure has been implemented to drive accountability, faster decision-making, and deeper engagement with Group Purchasing Organizations (GPOs). Supply reliability and fulfillment have continued to improve across the business, allowing the organization to shift from a defensive posture to a more proactive commercial offense. Management emphasized that the company does not require a strategic reset, as current investments are focused on driving simplification and leveraging strong existing market positions. Full-year organic revenue growth guidance is reaffirmed, with expectations for a second-half increase driven by normal seasonality and continued supply improvements. The fourth quarter 2026 relaunch of SurgiMend is expected to follow a phased approach, targeting historical high-volume users and key opinion leaders first. Management expects to achieve expanded PMA labels for SurgiMend and DuraSorb in 2027, providing both biologic and synthetic solutions for implant-based breast reconstruction. The company plans to refinance outstanding bank debt in the second half of 2026, assuming market conditions permit, which may lead to higher interest expense. Guidance for 2027 anticipates top-line growth and EPS expanding faster than sales, supported by an incremental $10 million to $15 million in annualized cost savings. Recent flooding in the Cincinnati area caused operational disruption at a manufacturing site, though management does not expect a material impact on 2026 guidance. Reported revenue outlook was lowered to reflect the negative impact of a stronger U.S. dollar on international sales. The company identified a $0.05 per share benefit from tariff favorability in Q2, which is being used to mitigate anticipated interest expense headwinds from future refinancing. MicroMatrix experienced a decline in the quarter due to increased competition from new entrants in the powder-form market. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management explained that the Q2 upside was primarily driven by $0.05 of tariff favorability and strong operational execution. The decision to hold the full-year guide reflects the use of tariff benefits to offset expected higher interest expenses from a planned debt refinancing in the second half. Stuart Essig clarified that there is no broader sales force restructuring; instead, the focus is on better coordination and leveraging existing GPO relationships. The only planned increase in the sales force will be specifically dedicated to supporting the SurgiMend ramp-up. Management expects a modest initial recovery, targeting approximately 50% of historical performance levels, similar to the successful PriMatrix relaunch. The 2026 guidance does not assume any meaningful revenue contribution from SurgiMend, as the focus is on building inventory and a controlled market re-entry. ENT performance was impacted by ongoing reimbursement pressures in sinus balloons, though MicroFrance instruments continued to grow. Management noted that the majority of their business is in trauma and acute care, providing insulation from fluctuations in elective procedure trends or insurance enrollment shifts.

PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2026. Second Quarter 2026 Highlights Second quarter revenues of $418.8 million increased 0.8% on a reported basis and 0.7% on an organic basis compared to the prior year. Second quarter GAAP earnings per diluted share of $0.06, compared to $(6.31) in the prior year. Adjusted earnings per diluted share of $0.56, compared to $0.45 in the prior year. The Company is updating its reported revenue guidance range to $1.654 billion to $1.695 billion to reflect the impact of a stronger U.S. dollar on foreign exchange rates. The Company is reaffirming its 2026 full-year organic revenue growth guidance of 0.8% to 3.3% and adjusted earnings per share guidance of $2.40 to $2.50. The Company initiated production at its Braintree manufacturing facility and remains on track for the planned fourth-quarter relaunch of SurgiMend®. "Our second-quarter performance reflects meaningful progress on our most important priorities. We are improving supply reliability, advancing quality, and returning products to market with discipline. The Braintree facility is now producing and ramping to support the planned SurgiMend relaunch later this year," said Stuart Essig, Chairman and CEO of Integra LifeSciences. "At the same time, we are seeing the benefits of a more aligned commercial organization while we continue to reduce our balance sheet leverage. Supported by our broad portfolio, attractive markets, and focused leadership team, we are strengthening our operating foundation and enhancing our ability to deliver sustainable long-term shareholder value." Second Quarter 2026 Consolidated Performance Total reported revenues of $418.8 million increased 0.8% on a reported basis and 0.7% on an organic basis compared to the prior year. The Company reported GAAP gross margin of 52.5%, compared to 50.4% in the second quarter of 2025. Adjusted gross margin was 61.3%, compared to 60.7% in the prior year. Adjusted EBITDA for the second quarter of 2026 was $78.4 million, or 18.7% of revenue, compared to $71.2 million, or 17.1% of revenue, in the prior year. The Company reported GAAP net income of $4.5 million, or $0.06 per diluted share, in the second quarter of 2026, compared to GAAP net loss of $(484.1) million, or $(6.31) per diluted share, in the prior year. Adjusted net income for the second quarter of 2026 was $43.7 million, or $0.56 per diluted share, compared to $34.4 million, or $0.45 per diluted share, in the prior year. Second Quarter 2026 Segment Performance Specialty Surgery (~70% of Revenues) Total revenues were $309.3 million, representing reported growth of 1.7% and an organic growth of 1.6% compared to the second quarter of 2025. Sales in Neuro increased 1.9% on an organic basis primarily driven by growth in Certas® Plus, Bactiseal® and CUSA®. Sales in Instruments grew 3.2% on an organic basis. ENT sales declined (1.9%) as MicroFrance® ENT instrument growth was offset by declines in other products. Tissue Reconstruction (~30% of Revenues) Total revenues were $109.5 million, representing reported and organic declines of (1.9)% and (2.0)% respectively compared to the second quarter of 2025. Key drivers for the quarter include: Mid-single digit decline in wound reconstruction, driven by strong growth in DuraSorb® and the relaunch of PriMatrix®, offset by declines in MicroMatrix® and Integra Skin. Integra Skin faced a prior year comparison that included the clearance of back orders in the second quarter of 2025. Sales in private label grew 4.7%. Balance Sheet, Cash Flow and Capital Allocation The Company generated cash flow from operations of $22.8 million in the quarter. Net debt at the end of the quarter was $1.6 billion, and the consolidated total leverage ratio was 4.1x. As of the end of the quarter, the Company had total liquidity of approximately $496 million, including $274.1 million in cash plus short-term investments and the remainder available under its revolving credit facility. 2026 Revenue and Adjusted Earnings Per Share Guidance For the third quarter of 2026, the Company expects reported revenues in the range of $410 million to $425 million, representing reported growth of 2.0% to 5.7% and organic growth of 1.9% to 5.7%. The Company expects adjusted EPS in the range of $0.53 to $0.61 per share. The Company is updating its reported revenue outlook from a range of $1.662 billion to $1.702 billion to a range of $1.654 billion to $1.695 billion to reflect the impact of a stronger U.S. dollar on foreign exchange rates. For the full year 2026, the Company is reaffirming its organic revenue growth guidance of 0.8% to 3.3% and adjusted earnings per share guidance of $2.40 to $2.50. The adjusted EPS outlook reflects updated tariff assumptions, a higher interest rate environment, and potential debt refinancing actions. The Company's organic sales growth guidance for the third quarter and full year excludes the impact of acquisitions, divestitures, and foreign currency. Conference Call and Presentation Available Online Integra has scheduled a conference call for 8:30 a.m. ET on Wednesday, July 29, 2026, to discuss second quarter 2026 financial results and forward-looking financial guidance. The conference call will be hosted by Integra's senior management team and will be open to all listeners. Additional forward-looking information may be discussed in a question-and-answer session following the call. Integra's management team will reference a presentation during the conference call, which can be found on the Investor section of the website at investor.integralife.com. A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, it is recommended to join 10 minutes prior to the event’s start. A webcast replay of the conference call will be available on the Investors section of the company's website following the call. About Integra Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com. Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like “will,” “believe,” “may,” “could,” “would,” “might,” “possible,” “should,” “expect,” “intend,” "forecast," "guidance," “plan,” “anticipate,” "target," or “continue,” the negative of these words, other terms of similar meaning or they may use future dates. Forward-looking statements contained in this news release include, but are not limited to, statements concerning: future business, operational and financial performance and the Company’s expectations and plans with respect to market opportunity, business and operational performance, strategic initiatives, capabilities, resources, manufacturing capabilities, product development, product availability and regulatory approvals, including expectations regarding the Company's Braintree facility and the the relaunch of SurgiMend in the fourth quarter of 2026. It is important to note that the Company’s goals and expectations are not predictions of actual performance. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited, to the following: increased geopolitical instability and other macroeconomic factors, including trade barriers and related restrictions (including tariffs and related countermeasures), armed conflict and acts of terrorism, geopolitical tension and instability, supply chain disruptions, and interest rate and foreign currency rate fluctuations, on the Company’s suppliers, vendors and customers and on the Company’s business and financial condition, results of operations and cash flows; the Company's ability to execute its financial, strategic and operating plans effectively; the Company's ability to remediate quality systems violations; difficulties in implementing the Company’s compliance master plan; difficulties or delays in obtaining and maintaining required regulatory approvals, including the costs thereof; potential difficulties, delays and disruptions in manufacturing, distribution or sale of products; the failure of the company’s suppliers, vendors, and other third parties to meet contractual, regulatory and other obligations; the anticipated development of markets the Company sells its products into and the success of the Company’s products in these markets; the Company’s ability to predict accurately the demand for its products and products under development; increasing industry competition; the coverage and reimbursement decisions of third-party payors; trends toward health care cost containment; difficulties in controlling expenses, including costs to procure and manufacture the Company’s products; the ability of the Company to successfully manage leadership and organizational changes and the impact of changes in management or staff levels; the impact of goodwill and intangible asset impairment charges if future operating results of acquired businesses are significantly less than the results anticipated at the time of the acquisitions, the geographic distribution of where the Company generates its taxable income; changes to applicable laws, regulations and enforcement guidance, including tax laws and global health care reforms; fluctuations in foreign currency exchange rates; the amount of our bank borrowings outstanding and other factors influencing liquidity; breaches, failures or other disruptions of our or our vendors’ or customers’ information technology systems or products; and the economic, competitive, governmental, technological, and other risk factors and uncertainties identified under the heading “Risk Factors” included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2025 and information contained in subsequent filings with the Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise, except as otherwise required by law. Discussion of Adjusted Financial MeasuresIn addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”), adjusted net income, adjusted gross margin, adjusted earnings per diluted share, and net debt. Organic revenues consist of total revenues excluding the effects of currency exchange rates, revenues from current-period acquisitions and product divestitures. Adjusted EBITDA consists of GAAP net income excluding: (i) depreciation and amortization; (ii) other income (expense); (iii) interest income and expense; (iv) income tax expense (benefit); (v) impairment charges; and (vi) those operating expenses also excluded from adjusted net income.   The measure of adjusted net income consists of GAAP net income, excluding: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) EU Medical Device Regulation-related charges; (iv) charges related to the transition of Boston-related manufacturing operations to the Company’s Braintree, Massachusetts facility (the "Braintree transition"); (v) intangible asset amortization expense; (vi) income tax impact from adjustments; and (vii) impairment charges.   The measure of adjusted gross margin is calculated by dividing adjusted gross profit by total revenues. Adjusted gross profit consists of GAAP gross profit adjusted for: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) charges related to Braintree transition; (iv) EU Medical Device Regulation-related charges; and (v) intangible asset amortization expense. The adjusted earnings per diluted share measure is calculated by dividing adjusted net income attributable to diluted shares by diluted weighted average shares outstanding. The measure of net debt consists of GAAP total debt (excluding deferred financing costs) less short-term investments, cash and cash equivalents. The Company has included reconciliations of GAAP revenues to organic revenues, GAAP net income to adjusted EBITDA, and adjusted net income, GAAP gross margin to adjusted gross margin, and GAAP earnings per diluted share to adjusted earnings per diluted share all for the quarters ended June 30, 2026 and 2025. The Company has included a reconciliation of GAAP total debt to net debt for the quarters ended June 30, 2026 and December 31, 2025. The Company is providing forward-looking guidance regarding organic revenue and adjusted earnings per diluted share but is not providing reconciliations to the most directly comparable forward-looking GAAP financial measures because certain GAAP expense items and the impact of changes in foreign exchange rates are highly variable and management is unable to predict them with reasonable certainty and without unreasonable effort. Specifically, the actual impact of changes in foreign exchange rates and the financial impact and timing of divestitures, acquisitions, integrations, structural optimization, efforts to comply with the EU Medical Device Regulation, and income tax impact from adjustments are uncertain, depend on various dynamic factors and are not reasonably ascertainable at this time. The unavailable information could have a material impact on GAAP results. The Company believes that the presentation of organic revenues and the other non-GAAP measures provide important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations.   For further information regarding why Integra believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company's Current Report on Form 8-K regarding this earnings press release filed today with the Securities and Exchange Commission. This Current Report on Form 8-K is available on the SEC's website at www.sec.gov or on our website at www.integralife.com. Investor Relations Contact:Chris Ward(609) [email protected] Media Contact:Laurene Isip(609) [email protected] INTEGRA LIFESCIENCES HOLDINGS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (In thousands, except per share amounts) The following table presents revenues disaggregated by the major sources for the three months ended June 30, 2026 and 2025 (amounts in thousands): (1) Organic revenues have been adjusted to exclude foreign currency (current period), acquisitions and to account for divested and discontinued products. Items included in GAAP net income and location where each item is recorded are as follows: (In thousands) Three Months Ended June 30, 2026 a) COGS - Cost of goods soldb) SG&A - Selling, general and administrativec) R&D - Research & developmentd) Amort. - Intangible asset amortizatione) OI&E - Other income & expensef) Tax - Income tax expense (benefit) Items included in GAAP net income and location where each item is recorded are as follows: (In thousands) Three Months Ended June 30, 2025 a) COGS - Cost of goods soldb) SG&A - Selling, general and administrativec) R&D - Research & developmentd) Amort. - Intangible asset amortizatione) OI&E - Other income & expensef) Tax - Income tax expense (benefit) (1) Adjusted net income for quarters ended June 30, 2026 and 2025 are reconciled above. Adjusted net income for remaining quarters in the trailing twelve months calculation have been previously reconciled and are publicly available in the Quarterly Earnings Call Presentations on our website at investor.integralife.com under Events & Presentations. The Company calculates adjusted free cash flow conversion by dividing its free cash flow by adjusted net income. The Company believes this measure is useful in evaluating the significance of the cash special charges in its adjusted earnings measures.

Interested in Integra LifeSciences Holdings Corporation? Here are five stocks we like better. Q2 results exceeded expectations: Revenue rose 0.8% to $419 million, while adjusted EPS increased 24% to $0.56, helped by better operational execution, manufacturing efficiencies and approximately $0.05 per share in tariff favorability. Full-year guidance was reaffirmed: Integra maintained organic revenue growth guidance of 0.8%–3.3% and adjusted EPS guidance of $2.40–$2.50, while raising the reported revenue range to account for foreign exchange impacts. Specialty Surgery and Neurosurgery grew, but Tissue Reconstruction and ENT remained under pressure. Deleveraging remains a priority: Operating cash flow improved to $22.8 million, and the leverage ratio fell to 4.1 times from 4.5 times at year-end 2025. Integra is preparing a controlled fourth-quarter relaunch of SurgiMend, though meaningful revenue contribution is not expected until beyond 2026. 3 Undervalued Midcaps Ready to Pop Integra LifeSciences (NASDAQ:IART) reported second-quarter 2026 revenue of $419 million, up 0.8% on a reported basis and 0.7% organically from a year earlier, as improving supply reliability and operational execution supported results. Adjusted earnings per share rose 24% year over year to $0.56, exceeding the company’s guidance range. Chairman, President and Chief Executive Officer Stuart Essig said the company delivered on its commitments during the quarter and continued to strengthen its operational foundation. “We are operating with greater consistency and strengthening our foundation for long-term growth,” Essig said. → This Tiny AI Supplier Could Be More Important Than the Chipmakers The company reaffirmed its full-year organic revenue growth outlook of 0.8% to 3.3% and its adjusted EPS guidance of $2.40 to $2.50. It updated its reported revenue outlook to $1.654 billion to $1.695 billion, reflecting the impact of foreign exchange rates and a stronger U.S. dollar. Chief Financial Officer Lea Knight said revenue delivery and transformation savings were in line with expectations, while stronger operational execution helped drive earnings to the high end of the company’s guidance range. Integra also benefited from approximately $0.05 per share of tariff favorability relative to its May outlook. → Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There? Gross margin reached 61.3%, compared with 60.7% in the prior-year period, reflecting manufacturing efficiencies and lower remediation spending. Adjusted EBITDA margin expanded 160 basis points to 18.7%. Knight said Integra retained its full-year EPS outlook because it has adjusted its tariff assumptions and expects higher interest expense in the second half tied to a potential refinancing of bank debt. The company still estimates its total tariff exposure for the year at about $0.10 per share. → Innovative ETF Strategies That Are Paying Off This Summer “We do not expect any operational headwinds to offset some of the upside that we saw, but we do expect to see interest expense headwinds,” Knight said. Integra expects third-quarter revenue of $410 million to $425 million, representing organic growth of 1.9% to 5.7%, and adjusted EPS of $0.53 to $0.61. Specialty Surgery revenue totaled $309.3 million, increasing 1.7% on a reported basis and 1.6% organically. Global Neurosurgery grew 1.9% organically, supported by demand for Certas Plus, CUSA and Bactiseal as supply fulfillment improved. Capital equipment sales declined about 1%, as double-digit CUSA growth was offset by lower sales of smaller-ticket capital equipment. Knight said Integra continues to view the hospital capital environment positively and expects capital equipment growth for the full year. Instruments revenue grew low single digits, benefiting partly from order timing compared with the first quarter. ENT revenue declined by low single digits, as growth in MicroFrance ENT instruments was more than offset by continuing pressure in sinus balloons. The company expects ENT revenue to decline for the full year and is focused on innovation in navigated systems and Eustachian-tube products to support longer-term growth. Essig said the company’s improved supply position allows the commercial organization to be more proactive. Its new commercial structure is designed to increase accountability, accelerate decision-making and expand enterprise contracting. Integra plans to leverage relationships with group purchasing organizations and integrated delivery networks built through its neurosurgery and specialty surgery businesses to support Tissue Reconstruction and ENT products. Tissue Reconstruction revenue was $109.5 million, down 1.9% on a reported basis and 2% organically. Wound Reconstruction was approximately flat for the first half of 2026 versus the prior year, a result management said remains consistent with its full-year expectations. Integra Skin increased sequentially from the first quarter but declined from the prior-year period, when revenue benefited from a significant clearance of product backorders. MicroMatrix also declined, which Knight attributed to increased competition from new powder-form product entrants. PriMatrix continued to gain traction following its relaunch. Essig said that about nine months after returning to the market, PriMatrix revenue had recovered to slightly more than 50% of pre-recall levels. He said the company has seen customer re-engagement and identified new opportunities while working to regain former customers. Integra has restarted manufacturing at its Braintree facility and is building inventory for a controlled fourth-quarter relaunch of SurgiMend 510(k) product. The company expects no meaningful SurgiMend contribution in 2026, but Essig said it expects share recapture to build across multiple quarters. He described a modest initial recovery, referencing approximately 50% of SurgiMend’s historical $40 million performance. The company is also pursuing PMA approvals for SurgiMend and DuraSorb in implant-based breast reconstruction. Essig said SurgiMend’s clinical safety and efficacy review has been completed and its PMA is pending a successful pre-approval inspection at Braintree. The company expects SurgiMend approval earlier in 2027 and DuraSorb approval later that year, subject to FDA timing and inspections. Separately, Essig said Integra continues work to return MediHoney to market in 2027, though no contribution is included in 2026 guidance. Operating cash flow was $22.8 million in the quarter, compared with $8.9 million a year earlier, despite including an $11 million final milestone payment related to the Sia acquisition. Free cash flow was $10.5 million, representing a 24% conversion rate. As of June 30, Integra had net debt of $1.6 billion and a consolidated total leverage ratio of 4.1 times, down from 4.5 times at the end of 2025. Total liquidity was approximately $496 million, including $274 million in cash and short-term investments. The company expects about a $150 million improvement in operating cash flow for 2026, driven by EBITDA growth, working-capital efficiency and lower cash expenditures related to EU MDR compliance and Braintree startup costs. Management said reducing leverage and repaying debt remain its top capital allocation priorities, with an objective of approaching the upper end of its 2.5-times to 3.5-times target leverage range by year-end. Knight also said flooding in the Cincinnati area recently disrupted operations at a manufacturing site. Based on available distribution-center inventory, secondary supply sources and insurance coverage, Integra does not expect the event to materially affect its 2026 revenue or EPS guidance. Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices. Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Integra LifeSciences Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for July 2026.

Medical device company Integra LifeSciences (NASDAQ:IART) met Wall Street’s revenue expectations in Q2 CY2026, but sales were flat year on year at $418.8 million. The company expects next quarter’s revenue to be around $417.5 million, close to analysts’ estimates. Its non-GAAP profit of $0.56 per share was 15.8% above analysts’ consensus estimates. Is now the time to buy Integra LifeSciences? Find out in our full research report. Revenue: $418.8 million vs analyst estimates of $417.7 million (flat year on year, in line) Adjusted EPS: $0.56 vs analyst estimates of $0.48 (15.8% beat) Adjusted EBITDA: $78.41 million vs analyst estimates of $73.52 million (18.7% margin, 6.7% beat) The company reconfirmed its revenue guidance for the full year of $1.67 billion at the midpoint Management reiterated its full-year Adjusted EPS guidance of $2.45 at the midpoint Operating Margin: 4.6%, down from 7.9% in the same quarter last year Free Cash Flow was $10.5 million, up from -$11.23 million in the same quarter last year Organic Revenue was flat year on year (beat) Market Capitalization: $1.54 billion "Our second-quarter performance reflects meaningful progress on our most important priorities. We are improving supply reliability, advancing quality, and returning products to market with discipline. The Braintree facility is now producing and ramping to support the planned SurgiMend relaunch later this year," said Stuart Essig, Chairman and CEO of Integra LifeSciences. Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ:IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments. A company’s long-term performance is an indicator of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Unfortunately, Integra LifeSciences’s 1.8% annualized revenue growth over the last five years was tepid. This fell short of our benchmarks and is a poor baseline for our analysis. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Integra LifeSciences’s annualized revenue growth of 2.6% over the last two years aligns with its five-year trend, suggesting its demand was consistently weak. We can better understand the company’s sales dynamics by analyzing its organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don’t accurately reflect its fundamentals. Over the last two years, Integra LifeSciences’s organic revenue averaged 2.1% year-on-year growth. Because this number aligns with its two-year revenue growth, we can see the company’s core operations (not acquisitions and divestitures) drove most of its results. This quarter, Integra LifeSciences’s $418.8 million of revenue was flat year on year and in line with Wall Street’s estimates. Company management is currently guiding for a 3.8% year-on-year increase in sales next quarter. Looking further ahead, sell-side analysts expect revenue to grow 3.3% over the next 12 months, similar to its two-year rate. This projection is underwhelming and suggests its newer products and services will not accelerate its top-line performance yet. ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention. AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice. Integra LifeSciences has managed its cost base well over the last five years. It demonstrated solid profitability for a healthcare business, producing an average adjusted operating margin of 19.2%. Analyzing the trend in its profitability, Integra LifeSciences’s adjusted operating margin decreased by 8.5 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 4.6 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn’t pass those costs onto its customers. This quarter, Integra LifeSciences generated an adjusted operating margin profit margin of 4.6%, down 9.9 percentage points year on year. This contraction shows it was less efficient because its expenses increased relative to its revenue. Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions. Sadly for Integra LifeSciences, its EPS declined by 4.6% annually over the last five years while its revenue grew by 1.8%. This tells us the company became less profitable on a per-share basis as it expanded due to non-fundamental factors such as interest expenses and taxes. Diving into the nuances of Integra LifeSciences’s earnings can give us a better understanding of its performance. As we mentioned earlier, Integra LifeSciences’s adjusted operating margin declined by 8.5 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals. In Q2, Integra LifeSciences reported adjusted EPS of $0.56, up from $0.45 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Integra LifeSciences’s full-year EPS to grow 5.9% from $2.47 to $2.61. It was good to see Integra LifeSciences beat analysts’ EPS expectations this quarter. We were also happy its EPS guidance for next quarter outperformed Wall Street’s estimates. On the other hand, its revenue guidance for next quarter was in line. Overall, this print had some key positives. The stock remained flat at $19.75 immediately after reporting. Big picture, is Integra LifeSciences a buy here and now? We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it’s free.

Integra LifeSciences (IART) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.45 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +16.67%. A quarter ago, it was expected that this medical device maker would post earnings of $0.41 per share when it actually produced earnings of $0.54, delivering a surprise of +31.71%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Integra, which belongs to the Zacks Medical - Instruments industry, posted revenues of $418.76 million for the quarter ended June 2026, missing the Zacks Consensus Estimate by 0.2%. This compares to year-ago revenues of $415.61 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Integra shares have added about 59.1% since the beginning of the year versus the S&P 500's gain of 8.5%. While Integra has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Integra was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.58 on $415.81 million in revenues for the coming quarter and $2.45 on $1.67 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Sight Sciences, Inc. (SGHT), has yet to report results for the quarter ended June 2026. The results are expected to be released on August 5. This company is expected to post quarterly loss of $0.15 per share in its upcoming report, which represents a year-over-year change of +34.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Sight Sciences, Inc.'s revenues are expected to be $21.75 million, up 11.2% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Integra LifeSciences Holdings Corporation (IART) : Free Stock Analysis Report Sight Sciences, Inc. (SGHT) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research